- Home
- ETON vs TNGX Comparison
ETON vs TNGX Comparison
Compare ETON & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- TNGX
- Stock Information
- Founded
- ETON 2017
- TNGX 2014
- Country
- ETON United States
- TNGX United States
- Employees
- ETON N/A
- TNGX N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ETON Health Care
- TNGX Health Care
- Exchange
- ETON Nasdaq
- TNGX Nasdaq
- Market Cap
- ETON 388.3M
- TNGX 351.2M
- IPO Year
- ETON 2018
- TNGX N/A
- Fundamental
- Price
- ETON $14.85
- TNGX $6.01
- Analyst Decision
- ETON Strong Buy
- TNGX Strong Buy
- Analyst Count
- ETON 3
- TNGX 6
- Target Price
- ETON $29.67
- TNGX $12.20
- AVG Volume (30 Days)
- ETON 636.4K
- TNGX 2.7M
- Earning Date
- ETON 08-07-2025
- TNGX 08-06-2025
- Dividend Yield
- ETON N/A
- TNGX N/A
- EPS Growth
- ETON N/A
- TNGX N/A
- EPS
- ETON N/A
- TNGX N/A
- Revenue
- ETON $48,327,000.00
- TNGX $40,990,000.00
- Revenue This Year
- ETON $103.21
- TNGX N/A
- Revenue Next Year
- ETON $51.34
- TNGX N/A
- P/E Ratio
- ETON N/A
- TNGX N/A
- Revenue Growth
- ETON 40.88
- TNGX 10.09
- 52 Week Low
- ETON $3.25
- TNGX $1.03
- 52 Week High
- ETON $21.48
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- ETON 54.31
- TNGX 76.36
- Support Level
- ETON $13.78
- TNGX $5.34
- Resistance Level
- ETON $16.27
- TNGX $6.40
- Average True Range (ATR)
- ETON 0.83
- TNGX 0.50
- MACD
- ETON 0.32
- TNGX -0.02
- Stochastic Oscillator
- ETON 77.67
- TNGX 84.08
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.